CIK Cells and HDAC Inhibitors in Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephan, David, Weiher, Hans, Schmidt-Wolf, Ingo G.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454858/
https://www.ncbi.nlm.nih.gov/pubmed/28468247
http://dx.doi.org/10.3390/ijms18050945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454858/
https://www.ncbi.nlm.nih.gov/pubmed/28468247
http://dx.doi.org/10.3390/ijms18050945

Ejemplares similares